Pluristem to advance blood transplant study

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
Webinar ReplaysDemystifying Sustainability Data Management and Regulatory Reporting
- 03/21/2023
- On-Demand
- 60 minutes
Webinar ReplaysThe 2022 Top Bank & Credit Union Rankings Release - National rankings
- 03/21/2023
- On-Demand
- 60 minutes
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

Blog

Essential IR Insights Newsletter - February 2023

27 Dec, 2016 | 04:55

Author Ayesha Hassan
Theme Healthcare & Pharmaceuticals

Pluristem Therapeutics Inc. is collaborating with the New York Blood Center to advance studies on its PLX-R18 therapy for umbilical cord blood transplantation.

The study will be funded by a conditional award of $900,000 from the Israel-U.S. Binational Industrial Research and Development Foundation with Pluristem providing the PLX-R18 cells and the NYBC conducting and supporting the studies.